Roivant Sciences Ltd. 's Pulmonary Hypertension Breakthrough Could Transform Its Growth Story Roivant Sciences Ltd.
's recent pulmonary hypertension breakthrough has sent shockwaves through the biotech industry, propelling its stock price up 18% in a single day.
The company's experimental treatment, mosliciguat, showed impressive results in Phase 2 trials, far exceeding expectations and sparking optimism about its potential to revolutionize the treatment of this debilitating condition.